TROV vs. PLX, IZTC, ACHL, ZIVO, CRTX, BLUE, CYTH, FNCH, JATT, and NKGN
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Protalix BioTherapeutics (PLX), Invizyne Technologies (IZTC), Achilles Therapeutics (ACHL), ZIVO Bioscience (ZIVO), Cortexyme (CRTX), bluebird bio (BLUE), Cyclo Therapeutics (CYTH), Finch Therapeutics Group (FNCH), JATT Acquisition (JATT), and NKGen Biotech (NKGN). These companies are all part of the "medical" sector.
Cardiff Oncology vs. Its Competitors
Protalix BioTherapeutics (NYSE:PLX) and Cardiff Oncology (NASDAQ:TROV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.
16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 10.0% of Cardiff Oncology shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 0.6% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Protalix BioTherapeutics has a net margin of -21.03% compared to Cardiff Oncology's net margin of -3,688.31%. Protalix BioTherapeutics' return on equity of -30.89% beat Cardiff Oncology's return on equity.
Protalix BioTherapeutics has a beta of -0.23, indicating that its stock price is 123% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.
In the previous week, Protalix BioTherapeutics had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 2 mentions for Protalix BioTherapeutics and 0 mentions for Cardiff Oncology. Protalix BioTherapeutics' average media sentiment score of 0.50 beat Cardiff Oncology's score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.
Protalix BioTherapeutics has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
Protalix BioTherapeutics currently has a consensus price target of $15.00, suggesting a potential upside of 870.87%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Protalix BioTherapeutics is more favorable than Cardiff Oncology.
Summary
Protalix BioTherapeutics beats Cardiff Oncology on 13 of the 16 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TROV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:TROV) was last updated on 7/5/2025 by MarketBeat.com Staff
